1P-ETH-LAD

1P-ETH-LAD (1-propionyl-6-ethyl-6-nor-lysergic acid diethylamide) is a synthetic psychedelic of the lysergamide family structurally derived from ETH-LAD. It is the N1-propionyl ester of ETH-LAD — meaning a propionyl group is attached to the nitrogen at position 1 of the lysergamide core. Like several other 1-acyl lysergamide designer drugs, 1P-ETH-LAD is widely believed to function as a prodrug that is rapidly cleaved by plasma esterases into the parent compound ETH-LAD following ingestion.

The subjective character of 1P-ETH-LAD closely resembles ETH-LAD but is consistently reported by experienced users to feel somewhat warmer, more visually elaborate, and more emotionally engaging than LSD at comparable doses. Community reports highlight that the onset is often slower than LSD (60–90 minutes) and that the experience tends toward the immersive and philosophical rather than the stimulating and analytical. The ethyl modification at the 6-position of the lysergamide nucleus appears to produce a more enveloping, sensory-rich experience compared to the diethyl amide substitution found in LSD.

1P-ETH-LAD emerged in the research chemical market around 2015, sold on blotter tabs. It gained rapid popularity among experienced psychedelic users who had encountered ETH-LAD and sought a legal analog with similar properties. Community experience with microdosing protocols emphasizes that 1P-ETH-LAD at sub-threshold doses (5–15 μg) can provide subtle mood and focus enhancement, though some users note residual visual disturbances at doses that would be completely sub-perceptual for LSD.

As with all lysergamide research chemicals, the long-term safety profile of 1P-ETH-LAD has not been formally studied. The risks are presumed to be similar to LSD and ETH-LAD but cannot be confirmed. Individuals with a personal or family history of psychosis or bipolar disorder should avoid this compound entirely. Testing with an Ehrlich reagent (purple/violet reaction) is essential before use to rule out more dangerous adulterants.